Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (The CAPS-PAH Study)

NCT02253394 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT02253394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02253394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (The CAPS-PAH Study)
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 4
Overall status
Terminated
Start date
September 30, 2015
Completion date
February 28, 2018
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension